List of Excipients in API ezetimibe and simvastatin
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ezetimibe and simvastatin
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Rebel Distributors Corp | VYTORIN | ezetimibe and simvastatin | 21695-325 | BUTYLATED HYDROXYANISOLE | |
| Rebel Distributors Corp | VYTORIN | ezetimibe and simvastatin | 21695-325 | CELLULOSE, MICROCRYSTALLINE | |
| Rebel Distributors Corp | VYTORIN | ezetimibe and simvastatin | 21695-325 | CITRIC ACID MONOHYDRATE | |
| Rebel Distributors Corp | VYTORIN | ezetimibe and simvastatin | 21695-325 | CROSCARMELLOSE SODIUM | |
| Rebel Distributors Corp | VYTORIN | ezetimibe and simvastatin | 21695-325 | HYPROMELLOSES | |
| Rebel Distributors Corp | VYTORIN | ezetimibe and simvastatin | 21695-325 | LACTOSE MONOHYDRATE | |
| Rebel Distributors Corp | VYTORIN | ezetimibe and simvastatin | 21695-325 | MAGNESIUM STEARATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing ezetimibe and simvastatin
Detailed excipient profiles for ezetimibe and simvastatin
Excipient focus: ANHYDROUS CITRIC ACID
ezetimibe and simvastatin drug variants containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-565 |
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-566 |
| >Company | >Ingredient | >NDC |
ezetimibe and simvastatin drug variants not containing ANHYDROUS CITRIC ACID
Excipient focus: ASCORBIC ACID
ezetimibe and simvastatin drug variants containing ASCORBIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-565 |
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-566 |
| Aurobindo Pharma Limited | ezetimibe and simvastatin | 59651-835 |
| >Company | >Ingredient | >NDC |
ezetimibe and simvastatin drug variants not containing ASCORBIC ACID
Excipient focus: BUTYLATED HYDROXYANISOLE
ezetimibe and simvastatin drug variants containing BUTYLATED HYDROXYANISOLE
ezetimibe and simvastatin drug variants not containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ezetimibe and simvastatin drug variants containing CELLULOSE, MICROCRYSTALLINE
ezetimibe and simvastatin drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CITRIC ACID MONOHYDRATE
ezetimibe and simvastatin drug variants containing CITRIC ACID MONOHYDRATE
ezetimibe and simvastatin drug variants not containing CITRIC ACID MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-565 |
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-566 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
ezetimibe and simvastatin drug variants containing CROSCARMELLOSE SODIUM
ezetimibe and simvastatin drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
ezetimibe and simvastatin drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-565 |
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-566 |
| >Company | >Ingredient | >NDC |
ezetimibe and simvastatin drug variants not containing FERRIC OXIDE RED
Excipient focus: FERRIC OXIDE YELLOW
ezetimibe and simvastatin drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-565 |
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-566 |
| >Company | >Ingredient | >NDC |
ezetimibe and simvastatin drug variants not containing FERRIC OXIDE YELLOW
Excipient focus: FERROSOFERRIC OXIDE
ezetimibe and simvastatin drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-565 |
| Actavis Pharma Inc | ezetimibe and simvastatin | 45963-566 |
| >Company | >Ingredient | >NDC |
ezetimibe and simvastatin drug variants not containing FERROSOFERRIC OXIDE
Excipient focus: HYPROMELLOSE
ezetimibe and simvastatin drug variants containing HYPROMELLOSE
ezetimibe and simvastatin drug variants not containing HYPROMELLOSE
Excipient focus: HYPROMELLOSE 2910
ezetimibe and simvastatin drug variants containing HYPROMELLOSE 2910
ezetimibe and simvastatin drug variants not containing HYPROMELLOSE 2910
Excipient focus: HYPROMELLOSES
ezetimibe and simvastatin drug variants containing HYPROMELLOSES
ezetimibe and simvastatin drug variants not containing HYPROMELLOSES
Excipient focus: ISOPROPYL ALCOHOL
ezetimibe and simvastatin drug variants containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | ezetimibe and simvastatin | 50090-4772 |
| Ascend Laboratories LLC | ezetimibe and simvastatin | 67877-507 |
| REMEDYREPACK INC | ezetimibe and simvastatin | 70518-1955 |
| >Company | >Ingredient | >NDC |
ezetimibe and simvastatin drug variants not containing ISOPROPYL ALCOHOL
Excipient focus: LACTOSE MONOHYDRATE
ezetimibe and simvastatin drug variants containing LACTOSE MONOHYDRATE
ezetimibe and simvastatin drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ezetimibe and simvastatin drug variants containing MAGNESIUM STEARATE
ezetimibe and simvastatin drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYL GALLATE
ezetimibe and simvastatin drug variants containing PROPYL GALLATE
ezetimibe and simvastatin drug variants not containing PROPYL GALLATE
| Company | Ingredient | NDC |
|---|---|---|
| Aurobindo Pharma Limited | ezetimibe and simvastatin | 59651-835 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
ezetimibe and simvastatin drug variants containing SODIUM LAURYL SULFATE
ezetimibe and simvastatin drug variants not containing SODIUM LAURYL SULFATE
Excipient focus: WATER
ezetimibe and simvastatin drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | ezetimibe and simvastatin | 50090-4772 |
| Ascend Laboratories LLC | ezetimibe and simvastatin | 67877-507 |
| REMEDYREPACK INC | ezetimibe and simvastatin | 70518-1955 |
| >Company | >Ingredient | >NDC |
ezetimibe and simvastatin drug variants not containing WATER
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links